Literature DB >> 2836616

The truncated form of the Epstein-Barr virus latent-infection membrane protein expressed in virus replication does not transform rodent fibroblasts.

D Wang1, D Liebowitz, E Kieff.   

Abstract

The gene encoding the Epstein-Barr virus membrane protein LMP, expressed in latent infection, is known to induce morphologic changes and some loss of contact inhibition in NIH 3T3 cells as well as profound loss of contact inhibition and of anchorage dependence in Rat-1 cells. Another form of LMP (D1LMP), deleted for the amino terminus and first four putative transmembrane domains of LMP, was recently shown to be expressed late in Epstein-Barr virus replication. We now demonstrate that D1LMP has no transformation-associated phenotypic effect in Rat-1 cells and does not significantly affect LMP-induced Rat-1 cell transformation. LMP activity and D1LMP inactivity in inducing anchorage-independent growth are not restricted to Rat-1 cells, but are also evident in BALB/c 3T3 cells. In both cell types, loss of contact inhibition and anchorage independence are acutely evident after LMP expression. Although newly transfected polyclonal Rat-1 or BALB/c cells have a lower agar cloning efficiency than established LMP-expressing clones, this is attributable, at least in part, to their lower average LMP expression, since among clones of transfected cells, higher cloning efficiencies correlated with higher levels of LMP. LMP is bound to the vimentin cytoskeletal network in rodent fibroblasts as it is in transformed lymphocytes, whereas D1LMP showed no detectable cytoskeletal binding, suggesting that cytoskeletal association may be integral to LMP-mediated cell transformation. LMP association with the cytoskeleton in latently infected, growth-transformed lymphocytes and LMP-transformed rodent fibroblasts, correlated with the lack of both rodent cell-transforming activity and cytoskeletal association of D1LMP supports working hypothesis that cytoskeletal association is important in LMP transforming activity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2836616      PMCID: PMC253390          DOI: 10.1128/JVI.62.7.2337-2346.1988

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

1.  A new technique for the assay of infectivity of human adenovirus 5 DNA.

Authors:  F L Graham; A J van der Eb
Journal:  Virology       Date:  1973-04       Impact factor: 3.616

2.  DNA sequence and expression of the B95-8 Epstein-Barr virus genome.

Authors:  R Baer; A T Bankier; M D Biggin; P L Deininger; P J Farrell; T J Gibson; G Hatfull; G S Hudson; S C Satchwell; C Séguin
Journal:  Nature       Date:  1984 Jul 19-25       Impact factor: 49.962

3.  Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter.

Authors:  P J Southern; P Berg
Journal:  J Mol Appl Genet       Date:  1982

4.  Step by step into carcinogenesis.

Authors:  J Cairns; J Logan
Journal:  Nature       Date:  1983 Aug 18-24       Impact factor: 49.962

5.  Nucleotide sequence of an mRNA transcribed in latent growth-transforming virus infection indicates that it may encode a membrane protein.

Authors:  S Fennewald; V van Santen; E Kieff
Journal:  J Virol       Date:  1984-08       Impact factor: 5.103

6.  Hormonal regulation of the Rous sarcoma virus src gene via a heterologous promoter defines a threshold dose for cellular transformation.

Authors:  E B Jakobovits; J E Majors; H E Varmus
Journal:  Cell       Date:  1984-10       Impact factor: 41.582

7.  A short sequence in the p60src N terminus is required for p60src myristylation and membrane association and for cell transformation.

Authors:  F R Cross; E A Garber; D Pellman; H Hanafusa
Journal:  Mol Cell Biol       Date:  1984-09       Impact factor: 4.272

8.  Phosphotyrosine-containing proteins and expression of transformation parameters in cells infected with partial transformation mutants of Rous sarcoma virus.

Authors:  J Cooper; K D Nakamura; T Hunter; M J Weber
Journal:  J Virol       Date:  1983-04       Impact factor: 5.103

9.  Factors governing the expression of a bacterial gene in mammalian cells.

Authors:  R C Mulligan; P Berg
Journal:  Mol Cell Biol       Date:  1981-05       Impact factor: 4.272

10.  Human metallothionein genes--primary structure of the metallothionein-II gene and a related processed gene.

Authors:  M Karin; R I Richards
Journal:  Nature       Date:  1982-10-28       Impact factor: 49.962

View more
  54 in total

1.  The late lytic LMP-1 protein of Epstein-Barr virus can negatively regulate LMP-1 signaling.

Authors:  K D Erickson; J M Martin
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Preferential localization of the Epstein-Barr virus (EBV) oncoprotein LMP-1 to nuclei in human T cells: implications for its role in the development of EBV genome-positive T-cell lymphomas.

Authors:  Jingwu Xu; Ali Ahmad; José Menezes
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

3.  Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation.

Authors:  J I Cohen; F Wang; J Mannick; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

4.  The only domain which distinguishes Epstein-Barr virus latent membrane protein 2A (LMP2A) from LMP2B is dispensable for lymphocyte infection and growth transformation in vitro; LMP2A is therefore nonessential.

Authors:  R Longnecker; C L Miller; X Q Miao; A Marchini; E Kieff
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

5.  Phenotypes of Epstein-Barr virus LMP1 deletion mutants indicate transmembrane and amino-terminal cytoplasmic domains necessary for effects in B-lymphoma cells.

Authors:  D Liebowitz; J Mannick; K Takada; E Kieff
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

6.  A selectable marker allows investigation of a nontransforming Epstein-Barr virus mutant.

Authors:  A Marchini; J I Cohen; F Wang; E Kieff
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

7.  Epstein-Barr virus latent membrane protein 1 (LMP-1) half-life in epithelial cells is down-regulated by lytic LMP-1.

Authors:  Jyotsna Pandya; Dennis M Walling
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

8.  (-)-Epigallocatechin-3-gallate inhibition of Epstein-Barr virus spontaneous lytic infection involves downregulation of latent membrane protein 1.

Authors:  Sufang Liu; Hongde Li; Min Tang; Ya Cao
Journal:  Exp Ther Med       Date:  2017-11-13       Impact factor: 2.447

9.  An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking.

Authors:  C L Miller; J H Lee; E Kieff; R Longnecker
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-18       Impact factor: 11.205

10.  Epstein-Barr virus latent membrane protein 2A blocks calcium mobilization in B lymphocytes.

Authors:  C L Miller; R Longnecker; E Kieff
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.